CDMO Hongene has announced that it will be supporting SiranBio's SA1211 programme.
SA1211 is a dual-target siRNA candidate for the treatment of chronic hepatitis B.
The company will provide support through its vertically integrated CDMO services spanning raw materials production, process and analytical development, cGMP drug substance and drug product manufacturing and regulatory and CMC support.
As next-generation siRNA therapeutics become more complex, the importance of strong capabilities in synthesis, impurity control, scale-up and clinical-stage manufacturing will increase, something the programme aims to address.
"Programmes like SA1211 show where the field is heading," said Dr David Butler, Chief Technology Officer at Hongene.
As siRNA designs become more complex, the bar for development and CMC execution rises with them.
"Our role is to give customers the technical depth and manufacturing flexibility to move these molecules forward with confidence."
Dr Butler added: "While SA1211 was manufactured using traditional solid-phase oligonucleotide synthesis, we are already applying our chemoenzymatic ligation platform to other complex dual-targeting siRNA programmes in development."
For next-generation constructs, we expect ligation to provide a highly attractive route to modular, high-purity and scalable manufacturing.
The SA1211 programme further reinforces Hongene's position as a specialised CDMO partner for innovative oligonucleotide therapeutics, particularly where molecular complexity and manufacturing execution are critical to programme success.